BMJ UK BMJ Americas BMJ Brazil BMJ China BMJ India

As a researcher, publishing your work is an important step in enhancing your academic career and ensuring your work has a wider impact. At BMJ, we are with you at every step of your publication journey and at any stage of your career. We can help you to optimise the presentation and impact of your work, and to disseminate your findings to the people who need to read it.

Publishing in one of our fully open access or transformative journals complies with policies set by funders (including Plan S), institutions and governments. Your institution may be part of an open access agreement with BMJ, which can help authors meet the cost of publishing (i.e. Article Processing Charge).

Options to publish your research open access at BMJ:

Fully open access journals Transformative journals    Hybrid  journals                       

Explore our journals in rheumatology







Acceptance rate: 31%

Time to first decision:                  36 days

Citescore: 7.7

Journal Impact Factor:          6.2

JIF Rank (Rheumatology):  6/34

*without review

Acceptance rate: 33%

Time to first decision:                  35 days

Citescore: 5

Journal Impact Factor:          3.9

JIF Rank (Rheumatology): 17/34 

Acceptance rate: 14%

Time to first decision:                  33 days

Citescore: 32.8

Journal Impact Factor:          27.4

JIF Rank (Rheumatology): 2/34 

Acceptance rate: 36%

Time to first decision*:          4 days

Citescore: 4.4

Journal Impact Factor:             2.9

JIF Rank (Medical, General & Internal): 77/167 


Acceptance rate: 15%

Time to first decision*:              3 days

Acceptance rate: 10%

Time to first decision:     56 days

Citescore: 15.3

Journal Impact Factor: 107.7

JIF Rank (Medical, General & Internal): 4/169

Reasons to publish your rheumatology research with us

Our open access content received on average 7 times more views than other content

Top open access articles mentioned in news outlets

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2


Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme


Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades

Listen to our experts explain our author support at BMJ


Resources for every stage of your publishing journey with BMJ

Before you submit Preparing your paper After submission Promoting your paper

Introducing our latest open access journals

Stay up to date with the latest research in rheumatology

Sign Up For Email Alerts

Contact us

For general queries, please contact our customer services team
We will respond to any online and email queries as soon as possible